These operational and strategic accomplishments have helped us achieve important financial goals. You may recall that during our December 2010 Investor Day, we laid out some long-term financial objectives. These included achievement of a compound annual non-GAAP EPS growth rate and operational TSR of at least 10% and 11%, respectively. Operational TSR being defined as EPS growth plus dividend yield. We have tracked well ahead of those trajectories in 2011 and 2012 and remain committed to those long-term goals.
Let me offer some observations about the quarter just completed, then I'll provide some color on our expectations for fiscal year 2013. We had a strong fourth quarter. Though our revenues were essentially flat, largely an outcome of brand-to-generic conversions, our non-GAAP EPS of $0.73 was up 22% versus last year's fourth quarter.
Our Pharma segment continued its strong performance, with 15% profit growth, as margins continued to expand. Performance under our branded agreement, new customer wins and strong contributions from our base of independent pharmacy customers contributed to profit growth.
Our pharma distribution business held its 21st Annual Retail Business Conference just a few weeks ago. We enjoyed the largest turnout to date, with nearly 7,500 people in attendance representing 4,100 pharmacies. The event provides peer-to-peer networking, buying opportunities, continuing education sessions and programs and technologies to help pharmacists improve patient care, efficiency and profitability.And lastly, we closed on our acquisition of the regional wholesaler, Dik Drug, giving us the opportunity to serve another 500 independent pharmacies. This acquisition is consistent with our strategy to both build out a retail independent customer base and grow our generics business.Our Specialty Solutions group posted another quarter of robust revenue growth. The business continues to build important relationships with both providers and payers by offering innovative and value-enhancing programs, as evidenced by increased revenues from both new and existing customers.Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV